DIADIA0.48%
SPYSPY0.10%
QQQQQQ1.12%
Trending
Top trending tickerDJTDJT3.71%
SHIBSHIB26.09%
MULLMULL14.50%
BRK.ABRK.A1.14%
QBTSQBTS5.21%
JASMYJASMY1.80%
TUTU1.09%
CRMDCRMD2.24%
VOYGVOYG4.32%
SPYSPY0.10%
Top trending tickerDJTDJT3.71%
SHIBSHIB26.09%
MULLMULL14.50%
BRK.ABRK.A1.14%
QBTSQBTS5.21%
JASMYJASMY1.80%
TUTU1.09%
CRMDCRMD2.24%
VOYGVOYG4.32%
SPYSPY0.10%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolDTILnews
Exchange: NASDAQ·Updated 07:34 PM EDT
DTIL logo

DTILPrecision Biosciences Inc

$7.29
$0.04
(0.55%)
Today
Closed $7.29
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$188.1M
Vol192,308.00
News
all
press releases
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precisions Board of Directors...
Business Wire
More News
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000 Index, effective at the close of U.S. equity...
Business Wire
Why Is Precision BioSciences Stock Gaining Wednesday?
Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.read more...
Benzinga
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study...
Business Wire
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will host an investor webcast to discuss new biopsy and clinical data from...
Business Wire
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire
Precision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS
Precision BioSciences (NASDAQ:DTIL - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -25.93% and +40.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.